DK1309593T3 - Substituerede pyrazoler - Google Patents

Substituerede pyrazoler

Info

Publication number
DK1309593T3
DK1309593T3 DK01965898T DK01965898T DK1309593T3 DK 1309593 T3 DK1309593 T3 DK 1309593T3 DK 01965898 T DK01965898 T DK 01965898T DK 01965898 T DK01965898 T DK 01965898T DK 1309593 T3 DK1309593 T3 DK 1309593T3
Authority
DK
Denmark
Prior art keywords
substituted pyrazoles
methods
pyrazoles
substituted
cathepsin
Prior art date
Application number
DK01965898T
Other languages
Danish (da)
English (en)
Inventor
Christopher R Butler
Darin J Gustin
Hui Cai
James P Edwards
Cheryl A Grice
Haripada Khatuya
Steven P Meduna
Barbara A Pio
Kevin L Tays
Jianmei Wei
Clark A Sehon
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of DK1309593T3 publication Critical patent/DK1309593T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
DK01965898T 2000-08-14 2001-08-10 Substituerede pyrazoler DK1309593T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22517800P 2000-08-14 2000-08-14
US09/927,324 US6953793B2 (en) 2000-08-14 2001-08-10 Substituted pyrazoles

Publications (1)

Publication Number Publication Date
DK1309593T3 true DK1309593T3 (da) 2006-07-17

Family

ID=26919364

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01965898T DK1309593T3 (da) 2000-08-14 2001-08-10 Substituerede pyrazoler

Country Status (20)

Country Link
US (2) US6953793B2 (hu)
EP (1) EP1309593B1 (hu)
JP (1) JP5049447B2 (hu)
KR (1) KR100837193B1 (hu)
AT (1) ATE320427T1 (hu)
AU (2) AU2001286454B2 (hu)
BR (1) BRPI0113286B8 (hu)
CA (1) CA2419552C (hu)
CZ (1) CZ307185B6 (hu)
DE (1) DE60118004T2 (hu)
DK (1) DK1309593T3 (hu)
ES (1) ES2261463T3 (hu)
HK (1) HK1055422A1 (hu)
HU (1) HU230538B1 (hu)
MX (1) MXPA03001422A (hu)
NZ (1) NZ524191A (hu)
PL (1) PL213103B1 (hu)
PT (1) PT1309593E (hu)
RU (1) RU2317988C2 (hu)
WO (1) WO2002014315A2 (hu)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
CN1329392C (zh) * 2000-08-14 2007-08-01 奥索-麦克尼尔药品公司 取代的吡唑
DE60118004T2 (de) * 2000-08-14 2006-11-16 Ortho-Mcneil Pharmaceutical, Inc. Substituierte pyrazole
US20050101587A9 (en) * 2000-08-14 2005-05-12 Butler Christopher R. Method for treating allergies using substituted pyrazoles
EP1383748A2 (en) * 2000-12-22 2004-01-28 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
WO2002085357A1 (en) * 2001-04-18 2002-10-31 Euro-Celtique, S.A. Nociceptin analogs
IL158486A0 (en) * 2001-04-18 2004-05-12 Euro Celtique Sa Nociceptin analogs
US20040147503A1 (en) * 2002-06-04 2004-07-29 Sheila Zipfeil Novel compounds and compositions as cathepsin inhibitors
RU2391094C2 (ru) 2002-09-24 2010-06-10 Новартис Аг Применение агониста рецептора s1p и способ лечения, облегчения или задержки прогрессирования неврита зрительного нерва или демиелинизационных заболеваний
US7109243B2 (en) 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
US7384970B2 (en) 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
US7173051B2 (en) 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
US7256207B2 (en) 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
FR2885904B1 (fr) * 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
CN101242839B (zh) * 2005-06-22 2012-11-07 凯莫森特里克斯股份有限公司 氮杂吲唑化合物及其制药用途
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
CL2007003590A1 (es) * 2006-12-12 2008-02-29 Wyeth Corp Compuestos derivados de aril sulfamida; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en prevencion y tratamiento de sintomas vasomotrices, disfuncion sexual, transtornos gastrointestinales, transt
US20080269241A1 (en) * 2007-02-15 2008-10-30 Darin Allen Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20090118274A1 (en) * 2007-02-15 2009-05-07 Darin Allen Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20090099157A1 (en) * 2007-02-15 2009-04-16 Ameriks Michael K Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s
US20080200454A1 (en) * 2007-02-15 2008-08-21 Ameriks Michael K Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20080207683A1 (en) * 2007-02-15 2008-08-28 Darin Allen Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
CN104800196A (zh) 2008-06-20 2015-07-29 诺华股份有限公司 用于治疗多发性硬化的儿科组合物
PE20110368A1 (es) * 2008-08-18 2011-06-13 Univ Yale Moduladores de mif
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
TWI475020B (zh) * 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
EP2464646B1 (en) * 2009-08-12 2014-05-07 Janssen Pharmaceutica, N.V. Process for the preparation of cathepsin s inhibitors
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
PL3176170T3 (pl) 2012-06-13 2019-05-31 Incyte Holdings Corp Podstawione związki tricykliczne jako inhibitory fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
CA2890018A1 (en) 2012-11-05 2014-05-08 Nant Holdings Ip, Llc Substituted indol-5-ol derivatives and their therapeutical applications
WO2014078257A1 (en) 2012-11-14 2014-05-22 Glaxosmithkline Llc Thieno[3,2-c]pyridin-4(5h)-ones as bet inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014145403A1 (en) 2013-03-15 2014-09-18 Nantbio, Inc. Substituted indol-5-ol derivatives and their therapeutic applications
PT2986610T (pt) 2013-04-19 2018-03-09 Incyte Holdings Corp Heterociclos bicíclicos como inibidores de fgfr
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3227282B1 (en) * 2014-12-02 2019-04-03 F.Hoffmann-La Roche Ag Novel piperidine derivatives
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2751669T3 (es) 2015-02-20 2020-04-01 Incyte Corp Heterociclos bicíclicos como inhibidores FGFR
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
LT3319959T (lt) 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
TWI770104B (zh) 2017-01-11 2022-07-11 美商羅登醫療公司 組蛋白去乙醯酶雙環抑制劑
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MX2020001484A (es) 2017-08-07 2020-08-20 Rodin Therapeutics Inc Inhibidores bicíclicos de la histona desacetilasa.
CN111295094A (zh) 2017-10-09 2020-06-16 泰尔茂比司特生物技术有限公司 冻干容器及使用冻干容器的方法
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
KR20210018264A (ko) 2018-05-04 2021-02-17 인사이트 코포레이션 Fgfr 억제제의 염
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CA3224729A1 (en) 2019-03-14 2020-09-17 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
PE20221085A1 (es) 2019-10-14 2022-07-05 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US856514A (en) * 1907-03-15 1907-06-11 William T Adams Cheese-cutter.
US3743409A (en) 1971-06-11 1973-07-03 Xerox Corp Cutter assembly
JPS5090172A (hu) 1973-12-13 1975-07-19
US3994890A (en) 1974-01-31 1976-11-30 Chugai Seiyaku Kabushiki Kaisha 1-Aminoalkyl, 3-phenyl indazoles
JPS5640714B2 (hu) * 1974-03-04 1981-09-22
DK27383A (da) 1982-02-17 1983-08-18 Lepetit Spa Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner
JPH0615542B2 (ja) 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
FR2642759B1 (fr) 1989-02-09 1991-05-17 Laboratorios Esteve Sa Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante
FR2673628B1 (fr) 1991-03-07 1993-07-09 Esteve Labor Dr Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles.
US5264576A (en) 1992-10-22 1993-11-23 Hoechst-Roussel Pharmaceuticals Incorporated Pyrazolo[4,3-c]pyridines which are intermediates
FR2705962B1 (fr) * 1993-06-03 1995-07-13 Rhone Poulenc Agrochimie Arylpyrazoles fongicides.
FR2712808B1 (fr) 1993-11-25 1996-02-16 Esteve Labor Dr Utilisation des dérivés de 1-{4-[4-aryl(ou hétéroaryl)-1-pipérazinyl]-butyl}-1-H-azole pour la préparation de médicaments destinés au traitement des troubles de la sécrétion gastrique .
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
WO1996030353A1 (en) 1995-03-24 1996-10-03 Arris Pharmaceutical Corporation Reversible protease inhibitors
US5776718A (en) 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
TW438591B (en) 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors
FR2742052B1 (fr) 1995-12-12 1998-04-10 Esteve Labor Dr Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports
ES2208898T5 (es) 1996-04-22 2009-04-16 Massachusetts Institute Of Technology Supresion de la respuesta inmune a traves de la inhibicion de la catepsina s.
AU7553198A (en) * 1997-06-12 1998-12-30 Sumitomo Pharmaceuticals Company, Limited Pyrazole derivatives
NZ503889A (en) 1997-11-05 2002-07-26 Novartis Ag Dipeptide nitriles
GB9806287D0 (en) 1998-03-24 1998-05-20 Synphar Lab Inc Monobactam enzyme inhibitors
WO1999058153A1 (en) 1998-05-08 1999-11-18 Brigham & Women's Hospital Methods of diagnosing and modulating autoimmunity
JP2002537294A (ja) 1999-02-20 2002-11-05 アストラゼネカ アクチボラグ カテプシンｌ及びカテプシンｓの阻害剤としてのジ−及びトリペプチドニトリル誘導体
US6395897B1 (en) 1999-03-02 2002-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5
TW200404789A (en) 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
ATE326454T1 (de) 1999-07-30 2006-06-15 Boehringer Ingelheim Pharma Neue bernsteinsäure derivative als cysteine- protease-inhibitoren
IL148630A0 (en) 1999-09-16 2002-09-12 Axys Pharm Inc Compounds and pharmaceutical compositions for inhibiting cathepsin s
AU1650501A (en) 1999-12-03 2001-06-12 Ono Pharmaceutical Co. Ltd. 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
DE60118004T2 (de) * 2000-08-14 2006-11-16 Ortho-Mcneil Pharmaceutical, Inc. Substituierte pyrazole

Also Published As

Publication number Publication date
KR100837193B1 (ko) 2008-06-13
MXPA03001422A (es) 2004-01-26
CA2419552A1 (en) 2002-02-21
BR0113286B1 (pt) 2013-04-16
RU2317988C2 (ru) 2008-02-27
CA2419552C (en) 2010-10-12
PL213103B1 (pl) 2013-01-31
AU2001286454B2 (en) 2006-09-14
BR0113286A (pt) 2003-09-09
PT1309593E (pt) 2006-08-31
CZ2003429A3 (cs) 2003-12-17
AU8645401A (en) 2002-02-25
US20030078419A1 (en) 2003-04-24
ES2261463T3 (es) 2006-11-16
WO2002014315A2 (en) 2002-02-21
CZ307185B6 (cs) 2018-03-07
DE60118004T2 (de) 2006-11-16
BRPI0113286B8 (pt) 2021-05-25
KR20030060876A (ko) 2003-07-16
HU230538B1 (hu) 2016-11-28
HK1055422A1 (en) 2004-01-09
EP1309593A2 (en) 2003-05-14
EP1309593B1 (en) 2006-03-15
US20050245576A1 (en) 2005-11-03
ATE320427T1 (de) 2006-04-15
HUP0303108A3 (en) 2012-10-29
WO2002014315A3 (en) 2002-06-13
NZ524191A (en) 2004-11-26
RU2003107016A (ru) 2004-11-27
JP2004511440A (ja) 2004-04-15
US6953793B2 (en) 2005-10-11
DE60118004D1 (de) 2006-05-11
PL360696A1 (en) 2004-09-20
HUP0303108A2 (hu) 2004-01-28
JP5049447B2 (ja) 2012-10-17

Similar Documents

Publication Publication Date Title
DK1309593T3 (da) Substituerede pyrazoler
DK1309592T3 (da) Substituerede pyrazoler
WO2002014314A3 (en) Substituted pyrazoles
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
MY158159A (en) Novel fused pyrrolocarbazoles
MY149041A (en) Novel fused pyrrolocarbazoles
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri
UA87829C2 (en) Fused pyrrolocarbazoles
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
SE0001631D0 (sv) New use